PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes |
| September 11, 2010 | September 2010 Bond Updates |
|
INCLINE VILLAGE, Nev., Sept. 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) affirmed that on September 15, 2010 it will redeem all of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 2023 (the "2023 Notes"). Holders of the 2023 Notes have been pro |
| View more at: http://www.prnewswire.com/news-releases/pdl-biopharma-provides-clarification-regarding-redemption-of-its-275-convertible-subordinated-notes-102643514.html |
| Related News |
|